Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?

Biogen is expected to report Q1 2026 EPS of $2.96 on revenue of $2.25 billion, but the outlook is mixed with pressure on MS drugs Tecfidera and Tysabri from generic and biosimilar competition. Growth in Vumerity, Skyclarys, Zurzuvae, and Alzheimer’s collaboration revenue should partly offset declines, though the quarter also includes about $34 million of IPR&D charges that could trim EPS. The company’s pending $5.6 billion cash acquisition of Apellis and a negative Earnings ESP of -2.17% are key discussion points ahead of the April 29 report.

Analysis

BIIB is shaping up as a quality-of-mix quarter rather than a clean top-line beat. The core tension is that legacy MS erosion is becoming less informative as a stock driver because new-product contribution is now large enough to offset a meaningful part of the decline; that shifts the debate from “can they defend the franchise?” to “can the launch portfolio compound fast enough to re-rate the multiple.” In practice, that means the market may tolerate a headline miss on older brands if Skyclarys, Zurzuvae, and Leqembi collaboration economics show enough sequential acceleration to validate a 2026-27 growth bridge.

The near-term risk is that consensus may be underestimating how much of the new-product upside is already anticipated in the share price after the past year’s run. The bigger second-order issue is margin quality: launch growth that is partially offset by IPR&D and integration-related chatter can produce better revenue optics without translating into durable EPS power, which is where the stock tends to lose momentum after beats. If management sounds more cautious on the timing of Apellis integration or on the cadence of Leqembi monetization, the market could reclassify BIIB from growth re-acceleration to value/defensive biotech.

Relative value is clearer than outright direction. SUPN is the cleaner long if the market focuses on Zurzuvae economics, because it gets direct profit-sharing leverage without the balance-sheet and pipeline overhangs BIIB carries. APLS is a probable trading beneficiary on deal probability and valuation support, but the spread should tighten once the transaction looks fully de-risked; the better setup is often the target rather than the acquirer when the buyer has execution risk and funding optics.

The contrarian view is that BIIB’s earnings setup is more balanced than the negative ESP implies. If the new-product mix beats even modestly, the stock can still rally because investors are positioned for a mediocre quarter; the asymmetry is that a clean print plus constructive guidance on launch durability could re-open the path toward multiple expansion, while a miss likely gets treated as transitory given the still-high contribution from newer assets.

Key Decisions for Investors

• Trade BIIB as a catalyst event, not a core long: consider buying a short-dated straddle into the print if implied move is below the likely revenue dispersion from new-product mix; upside is a rerating on launch momentum, downside is limited by already-cautious setup.
• Prefer SUPN over BIIB on a 1-3 month view: initiate a relative long SUPN / short BIIB pair if the market rewards Zurzuvae traction more than it penalizes BIIB legacy decay; this isolates the cleaner economic exposure.
• Watch APLS into deal-close headlines: buy pullbacks in APLS rather than chasing BIIB strength if the market is pricing in execution risk too aggressively; the spread can remain supported while takeover completion uncertainty fades over weeks, not days.
• If BIIB gaps up on a beat, use strength to fade into any move that is driven mainly by Leqembi optimism rather than sustained EPS revision, since IPR&D and integration chatter can cap multiple expansion.
• If BIIB gaps down on a modest miss but commentary confirms new-product sequential growth, consider a tactical long with a 4-8 week horizon; the stock can rebound quickly if the market concludes the launch mix is intact and the miss is legacy-driven.